Articles

Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market

This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.

EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU

Linvoseltamab has received EMA's Conditional Marketing Authorization for treating relapsed/refractory multiple myeloma, offering new hope for patients in the EU.

EU Clinical Trials Regulation Impact on Rare Disease Drug Development

This article examines the impact of the EU Clinical Trials Regulation on the development of drugs for rare diseases, focusing on challenges and opportunities for treatments.

EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27

The upcoming EU pharmaceutical legislation reform will significantly affect generics and biosimilars, shaping the future of drug access and innovation in 2026-27.

Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review

This article reviews the recent EU approvals of teclistamab and elranatamab, highlighting their significance in treating multiple myeloma.

EMA Conditional Approvals CAR-T: Insights on Relapsed B-Cell Lymphomas

This article delves into the insights and implications of EMA's conditional approvals for CAR-T therapies in the management of relapsed B-cell lymphomas.

EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval

This article delves into the EMA Conditional Approval Pathway, highlighting key insights from the oncology approval of Repotrectinib for advanced cancer treatment.

EU Clinical Trial Site Selection: Impact of New Qualification Requirements on Timelines

This article examines the implications of new qualification requirements on the timelines for clinical trial site selection in the EU, particularly for oncology drugs.

Biosimilars Growth in EU: Market Forecast Post-Biologics Patent Expiry

This article analyzes the anticipated growth of biosimilars in the EU following the patent expiry of major biologics, including Humira for rheumatoid arthritis.

Novel Immunotherapies Advanced Melanoma: EMA Approval & Phase 3 Insights

Discover the groundbreaking EMA-approved immunotherapies for advanced melanoma and insights from recent Phase 3 trials shaping future treatments.

Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact

This article delves into the market dynamics of biosimilar oncology antibodies, focusing on their role in cancer treatment and implications for healthcare systems.

HTA Outcomes Oncology Drugs: EU Regulation Impact on Germany, France, Italy

This article examines the effects of EU regulations on HTA outcomes for oncology drugs, focusing on implications for Germany, France, and Italy.

EU HTA Regulation Impact: Effects on Rare Disease Drug Approvals & Market Access

This article examines how the EU HTA Regulation influences the approval and market access of rare disease drugs, focusing on Zolgensma for spinal muscular atrophy.

European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates

This article delves into the EMA's regulatory framework for biomarker-driven trials, highlighting success rates and implications for drugs like Keytruda in treating melanoma.

EMA Conditional Marketing Authorizations: 5-Year Review of Oncology Drug Approvals

This article reviews the EMA's conditional marketing authorizations over the past five years, focusing on oncology drugs and their impact on cancer treatment accessibility.

EU Clinical Trial Ethics Committees: Analysis of Decision Patterns & Timelines

This article analyzes the decision-making patterns and timelines of EU Clinical Trial Ethics Committees, focusing on their impact on drug development in oncology.

Real-World Evidence Oncology Drugs: EMA vs MHRA Regulatory Approaches

This article compares the EMA and MHRA's regulatory frameworks for real-world evidence in oncology drugs, focusing on their implications for cancer treatment.

European Pediatric Investigation Plans: Accelerating Oncology Drug Development Timelines

European Pediatric Investigation Plans are crucial for expediting oncology drug development, ensuring timely access to innovative treatments for pediatric cancer patients.

HTA Outcomes Oncology Therapies: G-BA vs NICE Post-Brexit Analysis

This article analyzes HTA outcomes for oncology therapies, focusing on Keytruda's evaluation by G-BA and NICE in the post-Brexit landscape.

EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Development & Market Exclusivity

This article examines how recent EU pharmaceutical legislation reforms affect orphan drug development and market exclusivity, shaping the future of rare disease therapies.